All Stories

  1. Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes

    Article • Diabetes Care, December 2020, American Diabetes Association

    Professor Michael A. Nauck

  2. Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

    Article • Diabetes Care, October 2020, American Diabetes Association

    Professor Michael A. Nauck

  3. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

    Article • Diabetes Care, August 2020, American Diabetes Association

    Professor Michael A. Nauck

  4. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 201...

    Article • Diabetes Care, January 2020, American Diabetes Association

    Professor Michael A. Nauck

  5. Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII)

    Article • Journal of Diabetes Science and Technology, October 2019, SAGE Publications

    Professor Michael A. Nauck

  6. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial

    Article • Diabetes Care, August 2019, American Diabetes Association

    Professor Michael A. Nauck

  7. GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

    Article • Diabetes, April 2019, American Diabetes Association

    Professor Michael A. Nauck

  8. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial

    Article • Diabetes Obesity and Metabolism, October 2018, Wiley

    Professor Michael A. Nauck

  9. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus

    Article • International Journal of Clinical Practice, September 2018, Wiley

    Professor Michael A. Nauck

  10. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial

    Article • Diabetes and Vascular Disease Research, June 2018, SAGE Publications

    Professor Michael A. Nauck

  11. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

    Article • Diabetes Care, June 2018, American Diabetes Association

    Professor Michael A. Nauck

  12. Incretin hormones: Their role in health and disease

    Article • Diabetes Obesity and Metabolism, January 2018, Wiley

    Professor Michael A. Nauck

  13. A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers

    Article • Diabetic Medicine, July 2017, Wiley

    Professor Michael A. Nauck

  14. Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

    Article • Diabetes Obesity and Metabolism, May 2017, Wiley

    Professor Michael A. Nauck

  15. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

    Article • Diabetes Obesity and Metabolism, December 2016, Wiley

    Professor Michael A. Nauck

  16. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients

    Article • Diabetes Obesity and Metabolism, November 2016, Wiley

    Professor Michael A. Nauck

  17. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, November 2016, Wiley

    Professor Michael A. Nauck

  18. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

    Article • Diabetes Obesity and Metabolism, August 2016, Wiley

    Professor Michael A. Nauck

  19. Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial

    Article • Diabetes and Vascular Disease Research, May 2016, SAGE Publications

    Professor Michael A. Nauck

  20. Optimierte Basalratenprofile bei 339 Patienten mit Typ-1-Diabetes unter Insulinpumpenbehandlung

    Article • Diabetologie und Stoffwechsel, February 2016, Thieme Publishing Group

    Professor Michael A. Nauck

  21. Fasting C-peptide and Related Parameters Characterizing Insulin Secretory Capacity for Correctly Classifying Diabetes Type and for Predicting Insulin Requirement in Patients with Type 2 Diabetes

    Article • Experimental and Clinical Endocrinology & Diabetes, January 2016, Thieme Publishing Group

    Professor Michael A. Nauck

  22. Referat – Nächstes Gliptin im Test

    Article • Diabetologie und Stoffwechsel, January 2016, Thieme Publishing Group

    Professor Michael A. Nauck

  23. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

    Article • Diabetes Obesity and Metabolism, January 2016, Wiley

    Professor Michael A. Nauck

  24. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

    Article • Diabetes Obesity and Metabolism, September 2015, Wiley

    Professor Michael A. Nauck